C75.0 ICD-10-CM Code: Malignant neoplasm of parathyroid gland
C75.0 maps to CMS-HCC V28 23. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · free HCC coding tools
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of thyroid and other endocrine glands (C73-C75)
C75.0
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceMalignant neoplasm of parathyroid gland
Cancer that develops in the parathyroid glands, four small glands in the neck that regulate calcium levels in the blood.
Buddy Insight
Malignant neoplasm of the parathyroid gland is an exceedingly rare endocrine malignancy that typically presents with severe primary hyperparathyroidism and markedly elevated calcium and parathyroid hormone levels.
CMS-HCC V28
MappedHCC 23
Coefficient HCC 23: 0.186 (Community Non-Dual Aged (CNA))
CMS-HCC V24
HistoricalHistorical
Not used for CY2026 payment
ACA/HHS
MappedHCC 013
Code-level coefficient reference
ESRD/PACE
MappedHCC 12
Code-level coefficient reference
RXHCC
MappedHCC 22
Code-level coefficient reference
Code Book Path
Inclusion Terms
OfficialNo inclusion terms are included in this display for C75.0. Check the code and parent instructions in the Code Book.
Excludes 2
OfficialNo Excludes 2 notes are included in this display for C75.0. Check the code and parent instructions in the Code Book.
Related Codes
Includes
OfficialNo Includes notes are included in this display for C75.0. Check the code and parent instructions in the Code Book.
Excludes 1
Official- malignant carcinoid tumors (C7A.0-)Inherited from C75
- malignant neoplasm of adrenal gland (C74.-)Inherited from C75
- malignant neoplasm of endocrine pancreas (C25.4)Inherited from C75
- malignant neoplasm of islets of Langerhans (C25.4)Inherited from C75
- malignant neoplasm of ovary (C56.-)Inherited from C75
- malignant neoplasm of testis (C62.-)Inherited from C75
- malignant neoplasm of thymus (C37)Inherited from C75
- malignant neoplasm of thyroid gland (C73)Inherited from C75
- malignant neuroendocrine tumors (C7A.-)Inherited from C75
Code First
OfficialNo Code First sequencing instructions are included in this display for C75.0. Check the code and parent instructions in the Code Book.
Use Additional
OfficialNo Use Additional Code instructions are included in this display for C75.0. Check the code and parent instructions in the Code Book.
Code Also
OfficialNo Code Also instructions are included in this display for C75.0. Check the code and parent instructions in the Code Book.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is C75.0 an HCC code?
Yes. C75.0 (Malignant neoplasm of parathyroid gland) maps to HCC 23, Prostate, Breast, and Other Cancers and Tumors under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 0.186. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.
Coder answer: C75.0 is billable and maps to V28 HCC 23, Prostate, Breast, and Other Cancers and Tumors. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- C75.0
- Description
- Malignant neoplasm of parathyroid gland
- HCC (V28)
- HCC 23 — Prostate, Breast, and Other Cancers and Tumors
- RAF reference coefficient
- 0.186
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.
Work C75.0 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →
MEAT review for C75.0
For C75.0, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Coder workflow notes
Get the V28 mapping + MEAT cheat sheet
One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
C75.0 is the ICD-10-CM diagnosis code for malignant neoplasm of parathyroid gland. Cancer that develops in the parathyroid glands, four small glands in the neck that regulate calcium levels in the blood. C75.0 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of thyroid and other endocrine glands (c73-c75).
Under the CMS-HCC V28 risk adjustment model, C75.0 maps to Prostate, Breast, and Other Cancers and Tumors (HCC 23) with a source-labeled community, non-dual, aged reference coefficient of 0.186. No V24 mapping is shown for C75.0; use the applicable model and payment year when reviewing the V28 mapping. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.
Parathyroid carcinoma is rare; ensure documentation confirms malignancy and not benign parathyroid adenoma (which would be coded differently). For C75.0, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C75.0 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Parathyroid carcinoma is rare; ensure documentation confirms malignancy and not benign parathyroid adenoma (which would be coded differently)
- •Verify whether single or multiple parathyroid glands are involved, as this may affect staging and treatment decisions
Clinical Significance
Malignant neoplasm of the parathyroid gland is an exceedingly rare endocrine malignancy that typically presents with severe primary hyperparathyroidism and markedly elevated calcium and parathyroid hormone levels. Parathyroid carcinoma accounts for less than 1% of primary hyperparathyroidism cases, making accurate diagnosis and coding critical for treatment planning and surveillance.
Documentation Requirements
- ✓Pathology confirming parathyroid carcinoma — histological diagnosis is challenging and often requires expert review
- ✓Calcium and parathyroid hormone levels (typically markedly elevated in carcinoma vs. adenoma)
- ✓Documentation distinguishing from parathyroid adenoma (benign) which is far more common
- ✓Staging and extent of disease including any lymph node or distant metastases
- ✓Treatment status (surgical resection, monitoring of calcium levels)
Commonly Confused Codes
- •D35.1: Benign neoplasm of parathyroid gland: Parathyroid adenomas are benign and much more common
- •E21.0: Primary hyperparathyroidism: Hormonal condition caused by the tumor; code both when applicable
- •E83.52: Hypercalcemia: A manifestation of the parathyroid malignancy; code additionally when documented
- •C73: Malignant neoplasm of thyroid gland: Adjacent anatomy; verify parathyroid vs. thyroid origin
- •D44.2: Neoplasm of uncertain behavior of parathyroid gland: Use when malignancy is not confirmed